Healthcare Strategy Consulting

Today’s pharmaceutical, biotech and medical device companies face more formidable challenges than ever. Decision-makers grapple with increasing branded and generic competition, mounting payer pressures, declining R&D success rates, and constantly evolving therapeutic markets and geographies. The most successful companies continuously seek out opportunities to overcome key obstacles and maintain growth. These opportunities require deep insight, expert strategic capabilities, and deep scientific expertise. 

 

Leerink Swann Consulting (LSC) effectively helps our clients solve their toughest problems based on content expertise, focus and breadth of experience: 

 

  • A senior team with extensive management consulting and industry experience
  • Exclusive focus on Life Sciences and Healthcare
  • Deep perspective accumulated through hundreds of engagements every year
  • Access to cutting-edge research from our award-winning Equity Research team
  • Insights from more than 35,000+ healthcare professionals through the MEDACorp platform
  • An industry leading Investment Banking team


LSC partners with our clients to lead thinking on the following fronts:



Drive Corporate Growth (Back to Top)

Leerink Swann Consulting supports our clients in considering growth strategies and strategic options including In/Out-Licensing, M&A, Divestiture and Market Entry strategies:
  • Lead Licensing & Acquisition programs from search and screening to target identification, selection and commercial, clinical and regulatory due diligence
  • Carry out scenario and sensitivity analyses to assess valuation and sales forecasts for franchise strategies and potential pipeline portfolios
  • Explore strategic growth options in advance of planned IPOs for emerging companies

Expand into New Therapeutic Areas (Back to Top)

Our clients often maximize the value of their organizations by expanding into new therapeutic areas. We help align company assets and capabilities with today’s market opportunities by leveraging our ability to marry clinical and commercial domain expertise. Examples of our service offerings include:
  • Assist companies in understanding the global market opportunities for newly acquired assets
  • Support clients in evaluating the attractiveness of potential acquisition and/or in-licensing opportunities
  • Develop product and franchise strategies spanning new market and geographic opportunities (including 25+ engagements in oncology within the last 12 months)

Optimize R&D Portfolio and Tactics (Back to Top)

We help our clients sustain long-term growth by prioritizing R&D portfolios, conducting pipeline analyses and optimizing trial design to fit today’s current competitive, clinical and regulatory landscape.  Some examples include:
  • Support pharma and medical device companies in optimally balancing their R&D portfolios
  • Advise large BioPharma clients on using novel funding approaches (including “carve-outs”) to support future R&D investments
  • Help clients prioritize follow-on R&D opportunities for lead products based on analysis of emerging competitors

Launch Innovative Products (Back to Top)

Leerink Swann Consulting frequently helps develop early, mid, and late-stage launch strategies to help maximize revenue opportunities as clients commercialize new products. Key examples include:
  • Develop country-level launch playbooks to help global BioPharma companies position their portfolio in key developed markets (e.g., Japan) and emerging markets
  • Support development of payer planning activities - including customer segmentation - in new Emerging Markets for specialty products
  • Assist senior executives in building and optimizing organizational structure and functions, including the development of realistic project timelines and defining risk factors for new agents

Maximize Value of Existing Brands (Back to Top)

Our clients rely on today’s executives and brand managers to maximize the value of existing brands across the product lifecycle. We lead our clients to stronger commercial results through lifecycle planning, loss-of-exclusivity planning and payer access strategies. Examples of our service offerings include:
  • Work with cross-functional teams to diagnose brand performance and identify critical success factors for future growth
  • Assess loss of exclusivity strategies, including contracting and pricing opportunities for products facing generic competition
  • Helped BioPharma clients improve understanding of market access barriers and refine payer/provider value propositions

Achieve Capital Market Readiness (Back to Top)

LSC is uniquely positioned to help our early development stage clients understand key requirements and expectations for securing financing. Supported by leading insights from our Investment Banking colleagues, we help our clients move towards commercialization and find buy-side partners. Key examples include:
  • Assist early stage, venture funded medical device and Pharma companies understand the size, treatment and referral patterns for their products in order to support new financing efforts
  • Help development stage companies to identify and achieve critical determinants of success to support Series B financing efforts to fuel commercialization activities
  • Work with emerging companies to assess the core investment theses in order to successfully secure new company and project financing